Study: NCT02230046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment A)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment A)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment A)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment A)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment A)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment A)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.